Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2018) 132 (Supplement 1): 1371.

https://doi.org/10.1182/blood-2018-99-110200

Published: 2018

Journal Articles

Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma

Mark B. Meads, PhD, Paula Oliveira, Bin Fang, Praneeth Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Tuan Nguyen, Allison Distler, Salah-Eddin Komrokji, Aunshka Collins, Hongyue Dai, PhD, John M. Koomen, Ariosto Siqueira Silva, PhD, Kenneth H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 4411.

https://doi.org/10.1182/blood.V130.Suppl_1.4411.4411

Published: 2017

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Alexandra Keller, MSc, Barbara Peter, DVM, Johannes Zuber, MD PhD, Philipp Bernhard Staber, MD PhD, Peter Bettelheim, MD, Peter Valent, MD, Emir Hadzijusufovic, DVM

Blood (2015) 126 (23): 2829.

https://doi.org/10.1182/blood.V126.23.2829.2829

Published: 2015

Journal Articles

Targeting Polo-like Kinase in Acute Myeloid Leukemia

Chae Yin Cher, Cheuk Him Man, Stephen S.Y. Lam, Eric S.K. Ho, Nelson K.L. Ng, Marie-Anne Hospital, Jerome Tamburini, Anskar Y.H. Leung, MD

Blood (2014) 124 (21): 2234.

https://doi.org/10.1182/blood.V124.21.2234.2234

Published: 2014

Journal Articles

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

Elisa Leo, PhD, Giorgia Simonetti, PhD, Manuela Mancini, PhD, Nevena Veljkovic, PhD, Virginia Campi, Fausto Castagnetti, MD, Gabriele Gugliotta, MD, Caterina De Benedittis, Maria Alessandra Santucci, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 3125.

https://doi.org/10.1182/blood.V124.21.3125.3125

Published: 2014

Journal Articles

Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target

Tai-Chung Huang, M.D., Shubhada Shashikant Bharne, Ph.D., Jevon Cutler, Jun Zhong, Ph.D., David M. Weinstock, MD, Jeffrey W. Tyner, Curt I. Civin, M.D., Akhilesh Pandey, M.D., Ph.D.

Blood (2013) 122 (21): 2667.

https://doi.org/10.1182/blood.V122.21.2667.2667

Published: 2013

Journal Articles

The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition.

Karoline V. Gleixner, Harald Herrmann, Barbara Peter, Katharina Blatt, Karina Schuch, Winfried F Pickl, Christian Sillaber, Peter Valent

Blood (2010) 116 (21): 3394.

https://doi.org/10.1182/blood.V116.21.3394.3394

Published: 2010

Journal Articles

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

Annelies G. Renner, Cédric Dos Santos, Christian Recher, Christian Bailly, Laurent Créancier, Anna Kruczynski, Bernard Payrastre, Stéphane Manenti

Blood (2009) 114 (3): 659–662.

https://doi.org/10.1182/blood-2008-12-195867

Published: 2009

Includes: Supplemental data

Journal Articles

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Douglas W. McMillin, PhD, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Jana Jakubikova, Renee Wright, Nathanael Gray, PhD, Andrew Kung, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2764.

https://doi.org/10.1182/blood.V112.11.2764.2764

Published: 2008

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Kang-Hun Lee, MD, Richard F. Schlenk, MD, Gesine Bug, MD, Carsten Müller-Tidow, MD, Ralph M. Waesch, MD, David Nachbaur, MD, Peter Valent, MD, Gerd Munzert, MD, Frank Fleischer, PhD, Hartmut Dohner, MD, PhD, Pilar Garin-Chesa, PhD

Blood (2008) 112 (11): 2641.

https://doi.org/10.1182/blood.V112.11.2641.2641

Published: 2008

Journal Articles

Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Julie M. Vose, Anas Young, Jonathan W. Friedberg, Edmund K. Waller, Bruce D. Cheson, Dirk Trommeshauser, Gerd Munzert

Blood (2008) 112 (11): 233.

https://doi.org/10.1182/blood.V112.11.233.233

Published: 2008

Journal Articles

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

Roger Sidhu, MD, Tara Steffler, Gail Hipperson, Michelle Jung, Joyce Fung, Linda M. Pilarski, PhD, Andrew R. Belch, MD, Tony Reiman, MD, MSc

Blood (2007) 110 (11): 2514.

https://doi.org/10.1182/blood.V110.11.2514.2514

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3554.

https://doi.org/10.1182/blood.V110.11.3554.3554

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1046.

https://doi.org/10.1182/blood.V110.11.1046.1046

Published: 2007

NARROW

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Targeting Polo-like Kinase in Acute Myeloid Leukemia

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target

The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition.

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only